EAT-Lancetダイエットの遵守と刺激性腸症候群と機能性消化不全の確率:イスファハン機能障害 (ISFUN) 研究
Asma Salari-Moghaddam1,2, Awat Feizi3, Parisa Hajihashemi4
1Health and Environment Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Nutrition journal
|August 30, 2025
まとめ
EAT-Lancetダイエットへの従順性の低下は,刺激性腸症候群 (IBS) の発生率の増加と関連しています. この研究は,EAT-Lancetダイエットが消化器の健康に与える重要性を強調しています.
科学分野:
- 栄養学
- 胃腸内科
- 公衆衛生
背景:
- EAT-LancetダイエットとIBSやFDのような胃腸疾患の関係はまだ研究されていません.
- この研究は EAT-LancetダイエットとIBSとFDとの関連を調査することで,ギャップを埋めています.
- EAT-Lancetダイエットでは 植物性食品と動物性食品の消費を減らすことが重視されています
研究 の 目的:
- EAT-LancetダイエットとIBSとFDの発症の可能性との関連を調べる.
- 機能的胃腸疾患における持続的な食事パターンの役割についての洞察を提供すること.
主な方法:
- 健康な1892人のイラン人成人を対象とした横断的な研究.
- 食事の摂取量は106項目の食事頻度アンケートで評価された.
- EAT-Lancetダイエットインデックス (ELD-I) は,アデバーンスを測定するために計算され,ローマIV基準を用いてIBSとFDを診断した.
主要な成果:
- 刺激性腸症候群 (IBS) の罹患率は5. 29%,機能性消化不良 (FD) の罹患率は3. 17%でした.
- EAT-Lancetダイエットへの従順性の低下は,IBSの確率の増加と有意な正の関連性を示した (OR: 1.74; 95% CI: 1. 00- 3. 04).
- EAT- LancetダイエットとFDの確率 (OR:1. 37; 95% CI: 0. 65- 2. 89) の間に有意な関連性が見つかりませんでした.
結論:
- EAT-Lancetダイエットの遵守が低ければ,IBSの発症率が高くなるという.
- これらの発見を確認し,因果関係を調査するために,さらなる研究が推奨されます.
- EAT-Lancetダイエットは,IBSの予防や管理に役割を果たす可能性があります.
関連する概念動画
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
01:17Irritable Bowel Syndrome I: Introduction
369
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
369
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
294
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
294
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
238
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
238
01:17Chronic Bowel Disorders: Introduction
540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
01:21Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326